<DOC>
	<DOCNO>NCT02291666</DOCNO>
	<brief_summary>Type 2 diabetes ( T2D ) could modulate CYP450 activity involve drug-metabolism cardiovascular homeostasis . We propose carry , first time , comprehensive characterization effect T2D expression activity major CYP450s . In study , patient T2D study since hyperglycaemia and/or hyperinsulinemia believe modulate CYP450s . This vicious cycle put patient risk micro- macro-vascular complication inadequately control T2D due high intersubject variability drug disposition action . Characterization effect T2D drug metabolism capacity perform use cocktail CYP450 probe drug . CYP450 phenotype determine 3 group patient ( n=126 patient ) : 1 ) 42 T2D patient good glycemic control ; 2 ) 42 T2D patient poor glycemic control ; 3 ) 42 non-T2D healthy subject follow single oral administration cocktail CYP450 probe drug . Subjects receive CRCHUM-MT cocktail consist caffeine ( CYP1A2 ) , bupropion ( CYP2B6 ) , tolbutamide ( CYP2C9 ) , omeprazole ( CYP2C19 ) , dextromethorphan ( CYP2D6 ) , midazolam ( CYP3A4/5 ) chlorxozaxone ( administer separately ) ( CYP2E1 ) . Serial blood sample draw urine collect . Metabolic ratio calculate compare three group subject . Other co-variables study include T2D biomarkers baseline ( glucose , insulin , HbA1c ) , medication , genetic polymorphism inflammatory marker . Our cocktail probe drug approach allow u demonstrate effect T2D activity major CYP450s . Moreover , project indicate u whether glycemic control consider covariate intersubject variability drug metabolism capacity .</brief_summary>
	<brief_title>Evaluation CYP450 Activities Diabetic Patients vs. Non-diabetic Subjects</brief_title>
	<detailed_description>Patients type 2 diabetes ( T2D ) require various therapeutic approach ( diet , exercise drug ) ensure glycaemic control minimize risk hypoglycaemia . T2D also associate vascular morbidity necessitate multiple drug prevent cardiovascular complication . Clinical practice reveals T2D patient show highly variable response different drug . Variable drug dosage effect observe drug clopidogrel , warfarin , cyclosporine tacrolimus , well anti-hypertensive , cholesterol lower antidiabetic drug . These observation strongly suggest T2D modulate factor regulate drug disposition and/or drug effect . The hypothesis underlie proposal : T2D abnormality alter expression activity CYP450s involve disposition drug use treat T2D associate comorbidities . The overall objective project investigate effect T2D activity several CYP450 isozymes . Primary objective : To compare CYP450 activity 3 group patient : 1 ) T2D patient good glycemic control ; 2 ) T2D patient poor glycemic control ; 3 ) non-T2D healthy subject follow single oral administration cocktail CYP450 probe drug . Study design ; Patients ( n=126 ) recruit constitute 3 group : Group I , 42 confirm T2D HbA1c ≤7.0 ; Group II , 42 patient poor glycemic control HbA1c &gt; 7.5 , Group III , 42 sexed-matched non-T2D healthy subject . This design allow u compare CYP450 activity T2D patient good glycemic control , T2D patient poor glycemic control , non-diabetic healthy subject . Participants ≥18 year old , body weight index ≤35 , non-smokers ( &gt; 3 month ) . Subjects recruit CHUM outpatient clinic . The T2D diagnosis establish accord Canadian clinical guideline . After overnight fast , participant admit CRCHUM 's Clinical Research Unit ( hospitalize ) . Subjects receive CRCHUM-MT cocktail ; 100mg caffeine , 100mg bupropion , 250mg tolbutamide , 20mg omeprazole , 30mg dextromethorphan 2mg midazolam phenotype CYP1A2 , 2B6 , 2C9 , 2C19 , 2B6 , 2D6 3A4/5 , respectively . Serial blood sample draw urine collect 8 hour follow drug administration . At end study day , subject discharge CRCHUM 's Clinical Research Unit oral 250mg dose chlorzoxazone ( CYP2E1 ) give urine collect overnight 12 hour . A blood sample take pharmacogenetic analysis relevant drug metabolize enzyme . Additional blood sample collect administration cocktail measure insulin , glycaemia HbA1c level , biomarkers inflammatory marker . The subject instruct take medication , caffeine theobromine containing product morning study day . Their regular medication administer 4 hour administration cocktail indicate . The subject probe marker drug use daily still enrol metabolic ratio determine establish CYP450 activity . Pharmacokinetic parameter oral clearance , metabolic clearance renal clearance determine noncompartmental analysis . Metabolic ratio calculate compare three group subject .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Chlorzoxazone</mesh_term>
	<mesh_term>Tolbutamide</mesh_term>
	<criteria>Participants ≥18 year old Body weight index ≤35 , Nonsmokers ( &gt; 3 month ) Patients type 2 diabetes good glycemic control ( A1C &lt; 7 ) poor glycemic control ( A1C &gt; 7.5 ) healthy nondiabetic subject eligible . Subjects estimate glomerular filtration ( MDRD ) &lt; 50mL/min/1.73m2 ALT AST 3 time upper limit normal Organ transplant recipient , inflammatory illness ( i.e. , polyarthritis , severe cirrhosis , infectious disease ) Previous history active cancer ( except nonmelanoma skin cancer ) Uncontrolled thyroid function Pregnant History drug alcohol abuse Subjects history current inflammatory bowel diseases include ulcerous colitis Crohn 's disease , bariatric surgery Drugs know modulate CYP450 activity , subject take one follow therapy exclude : antibiotic , antiviral , anticancers , CYP450 inducer ( carbamazepine , phenobarbital , phenytoin , rifampin , StJohn 's wort ) , CYP450 inhibitor ( amiodarone , fluvoxamine , fluoxetine , verapamil ) , immunosuppressor , warfarin , INFs , antibodies grapefruit juice ( &lt; 4 week ) investigational drug Intolerance hypersensitivity probe drug CRCHUMMT cocktail chlorzoxazone/acetaminophen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Cytochromes p450</keyword>
	<keyword>drug metabolism</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>diabetes</keyword>
	<keyword>probe marker</keyword>
</DOC>